Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 48M | 17.9% |
| Gross Profit | -9.9M | 45.3% |
| Cost of Revenue | 58M | 1.5% |
| Operating expense | 70M | 1.5% |
| Net Income | -23M | 29.6% |
| EBITDA | -25M | 24.5% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 376M | 0.1% |
| Total Liabilities | 139M | 11.4% |
| Total Equity | 237M | 5.9% |
| Shares Outstanding | 38M | 0.4% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -8.7M | 39.9% |
| Cash from investing | 3.1M | 107.7% |
| Cash from financing | 640,000 | 98.5% |
EPS
Financial Highlights for Tarsus Pharmaceuticals in Q3 '24
Tarsus Pharmaceuticals reported a revenue of 48M, which is a 17.9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -9.9M, marking a 45.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 58M, a -1.5% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 70M, showing a -1.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -23M, showing a 29.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -25M, showing a 24.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Tarsus Pharmaceuticals with growth in revenue, gross profit, and net income.
